DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,518,106
|Title:||Collagen fibrillar construction|
|Abstract:||Methods and compositions are described for organizing collagen into fibrillar networks, e.g, short and long-range organization. Collagen produced by the disclosed methods can be used for tissue engineering.|
|Inventor(s):||Saeidi; Nima (Allston, MA), Ruberti; Jeffrey W. (Lexington, MA)|
|Assignee:||Northeastern University (Boston, MA)|
|Patent Claims:||1. A method of producing an organized array of collagen fibrils, the method comprising: applying a tension to a plurality of collagen fibrils in a solution, wherein
the tension is controlled to generate a strain of about 1% to about 10% such that a controlled load on collagen monomers in the solution is produced; and adding a collagen lytic protease to the solution, thereby producing an organized array of collagen
2. The method of claim 1, further comprising neutralizing the pH of the solution.
3. The method of claim 2, further comprising neutralizing the pH of the solution at about 10.degree. C. to about 39.degree. C.
4. The method of claim 1, wherein the tension is applied to both ends of the plurality of collagen fibrils.
5. The method of claim 4, further comprising adding supplemental collagen monomers to the solution continuously when applying the tension.
6. The method of claim 5, wherein the collagen lytic protease and the supplemental collagen monomers are added simultaneously to the solution.
7. The method of claim 5, wherein the collagen lytic protease and the supplemental collagen monomers are added sequentially to the solution.
8. The method of claim 5, wherein the collagen lytic protease and the supplemental collagen are added more than once to the solution.
9. The method of claim 1, further comprising organizing the array of collagen fibrils into a tissue.
10. The method of claim 5, further comprising continuously extending a collagen fibrillar structure at a rate of from about 0.1 .mu.m/min to about 100 .mu.m/min.
11. The method of claim 10, further comprising adding collagen lytic protease to the solution while extending the collagen fibrillar structure.
12. The method of claim 10 or 11, further comprising extending the collagen fibrillar structure in the presence of a co-nonsolvency agent.
13. The method of claim 12, wherein the co-nonsolvency agent is polyethylene glycol, hyaluronic acid, a glycosaminoglycan, a proteoglycan, or a combination thereof.
14. The method of claim 13, wherein the proteoglycan is lumican, decorin, biglycan, perlecan, versican, fibromodulin, aggrecan, sydecan or a combination thereof.
15. The method of claim 1 or claim 11, wherein the collagen lytic protease is a bacterial collagenase, a matrix metalloproteinase, or cathepsin.
16. The method of claim 1, wherein the solution further comprises a collagen binding agent.
17. The method of claim 16, wherein the collagen binding agent is a proteoglycan, a glycoprotein, a collagen-binding portion thereof, or a combination thereof.
18. The method of claim 1, wherein the controlled load on each collagen monomer is from 1.0 piconewtons to 10.0 piconewtons.
19. The method of claim 1, wherein the controlled load on each collagen monomer is greater than 10.0 piconewtons.
20. The method of claim 1, further comprising adding a cross-linking agent to the solution.
21. The method of claim 20, wherein the cross-linking agent is added before applying the tension.
22. The method of claim 20, wherein the cross-linking agent is added after applying the tension.
23. The method of claim 20, wherein the cross-linking agent is formaldehyde, hexamethylene diisocyanate, glutaraldehyde, polyepoxy compounds, gamma irradiation, or ultraviolet irradiation with riboflavin.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Advance Biofactures||SANTYL||collagenase||VIAL||101995||001||1965-06-04||See Pricing||Northeastern University (Boston, MA)||2028-04-11||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.